Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Receives $177.00 Consensus Target Price from Analysts

Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report) has earned a consensus rating of "Moderate Buy" from the fifteen ratings firms that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $177.00.

JAZZ has been the topic of several research reports. TD Cowen reduced their price objective on Jazz Pharmaceuticals from $200.00 to $195.00 and set a "buy" rating on the stock in a report on Thursday, November 7th. Piper Sandler reaffirmed an "overweight" rating and set a $163.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Royal Bank of Canada reiterated an "outperform" rating and issued a $179.00 price objective on shares of Jazz Pharmaceuticals in a research report on Tuesday, December 10th. Cantor Fitzgerald reissued an "overweight" rating and set a $140.00 price objective on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. Finally, Robert W. Baird raised their target price on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an "outperform" rating in a research note on Monday, November 18th.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock traded down $3.20 during trading hours on Friday, reaching $120.56. 683,587 shares of the company were exchanged, compared to its average volume of 556,644. Jazz Pharmaceuticals has a fifty-two week low of $99.06 and a fifty-two week high of $134.17. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The stock's fifty day moving average is $121.03 and its two-hundred day moving average is $113.68. The company has a market cap of $7.29 billion, a price-to-earnings ratio of 16.98, a P/E/G ratio of 1.04 and a beta of 0.56.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,700 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $123.41, for a total value of $456,617.00. Following the transaction, the executive vice president now owns 33,048 shares of the company's stock, valued at approximately $4,078,453.68. The trade was a 10.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Bruce C. Cozadd sold 2,000 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $121.17, for a total transaction of $242,340.00. Following the sale, the chief executive officer now directly owns 427,025 shares of the company's stock, valued at $51,742,619.25. This represents a 0.47 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 6,753 shares of company stock valued at $816,289. Company insiders own 4.20% of the company's stock.

Institutional Trading of Jazz Pharmaceuticals

Institutional investors have recently modified their holdings of the company. CWA Asset Management Group LLC acquired a new stake in shares of Jazz Pharmaceuticals in the third quarter valued at approximately $3,197,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Jazz Pharmaceuticals by 135.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company's stock valued at $19,394,000 after buying an additional 100,112 shares during the last quarter. Franklin Resources Inc. lifted its position in Jazz Pharmaceuticals by 4.6% during the 3rd quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company's stock worth $124,208,000 after buying an additional 48,708 shares in the last quarter. Pacer Advisors Inc. lifted its position in Jazz Pharmaceuticals by 15.3% during the 3rd quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company's stock worth $233,892,000 after buying an additional 278,465 shares in the last quarter. Finally, Philip James Wealth Mangement LLC acquired a new position in shares of Jazz Pharmaceuticals during the 3rd quarter worth about $830,000. 89.14% of the stock is currently owned by institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.